Thyrocare Technologies Ltd
Please find attached the Investor Presentation on the Unaudited Financial Results (Standalone and Consolidated) for the quarter ended on June 30, 2026
RESULTS
▲ Positive Development
LOW RISK
📅 Filed on BSE: 23 Jul 2026, 04:05 PM IST · BSE ID: a01a6dde-e9a3-4114-a5a1-525ed77c8a9b
View Original BSE Filing (PDF)
💡
In Simple Terms
Thyrocare's latest financial results show significant increases in both sales and profits for the first quarter of fiscal year 2027.
🤖 AI Summary
- Consolidated revenue from operations for Q1 FY27 increased 24.3% YoY to INR 240.02 crore.
- Consolidated Profit After Tax (PAT) for Q1 FY27 grew 34.1% YoY to INR 51.33 crore.
- Standalone revenue from operations was INR 225.66 crore, a 26.1% YoY increase in Q1 FY27.
- Standalone PAT for Q1 FY27 rose 39.2% YoY to INR 50.17 crore.
- Patients increased 17% YoY to 5.4 Mn; tests conducted grew 28% YoY to 55.2 Mn in Q1 FY27.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Consolidated Revenue from operations
INR 240.02 crore
24.3%
Consolidated Profit After Tax
INR 51.33 crore
34.1%
Consolidated EBITDA
INR 77.27 crore
33.8%
Standalone Revenue from operations
INR 225.66 crore
26.1%
Standalone Profit After Tax
INR 50.17 crore
39.2%
Pathology Revenue (Rs Cr)
INR 225.6 Cr
26%
Quarterly Active Franchisees
11,730
23%
Tests performed (Mn)
55.2 Mn
28%
Radiology Revenue (INR crore)
INR 13.48 crore
-4.0%
🏢 How This Affects the Company
The company's pathology revenue grew 27% YoY, driven by a 23% increase in quarterly active franchisees to 11,730 and expansion with new regional and hybrid labs.
Consolidated Gross margin improved by 292 bps YoY to 74.1%, and EBITDA margin increased by 226 bps YoY to 32.2%, indicating enhanced operational efficiency and profitability.
Thyrocare launched new regional and hybrid labs, strengthened channel partner relationships through franchisee meetings, and conducted doctor feedback sessions to improve service delivery.
The Radiology business revenue declined 4.0% YoY, attributed to a strategic exit from non-profitable centers, which reduces exposure to underperforming assets.
👥 What This Means For Shareholders
✅
Action Required
No immediate action is required from shareholders based on this financial results update.
👤
Who Is Affected
All shareholders are affected by the company's financial performance, which reflects significant growth in revenue and profit metrics for Q1 FY27, including consolidated PAT up 34.1% YoY to INR 51.33 crore.
🔍
Management Signal
The management's focus on expanding the lab network, increasing franchisee base, and improving operational efficiency is evident through the reported Q1 FY27 performance.
For information only. Not investment advice. ForgeUp is not SEBI-registered.
👁 Watch List — track these upcoming events
Q2 FY27 financial results – observe sustained growth in consolidated revenue and PAT.
Updates on new lab launches and franchisee expansion initiatives.
Progress on new technology additions like Gut Microbiome and Whole Exome sequencing.
LOW RISK
The filing indicates a strategic exit from non-profitable radiology centers, reducing exposure to underperforming assets.
💡 Investor Takeaway
Thyrocare Technologies reported Q1 FY27 consolidated revenue of INR 240.02 crore, up 24.3% YoY, and consolidated PAT of INR 51.33 crore, a 34.1% YoY increase. Standalone PAT rose 39.2% YoY to INR 50.17 crore, with EBITDA margin at 33.5% for Q1 FY27.
⚖️ Strengths & Concerns
✅ Positives
- Consolidated PAT increased 34.1% YoY to INR 51.33 crore, reflecting improved profitability and operational performance.
- Pathology revenue grew 27% YoY to INR 142.8 crore, supported by a 23% YoY increase in active franchisees to 11,730.
⚠️ Concerns
- Radiology business revenue declined 4.0% YoY to INR 13.48 crore in Q1 FY27, despite an EBITDA growth of 23.1%.
- Revenue per test decreased by 2% YoY to INR 39.8, while revenue per patient increased 7% YoY to INR 404.
📅 Company Track Record
Thyrocare Technologies reported Q1 FY27 revenue up 24% to INR 240.02 crore and PAT up 34% YoY, as per previous filing on July 23, 2026. This follows the Q1 FY27 earnings call announcement on July 16, 2026. Board had approved Q1 FY27 results and re-appointed internal auditor on July 23, 2026.
Based on publicly available historical data. For context only.
❓ Frequently Asked Questions
What was Thyrocare Technologies' consolidated revenue in Q1 FY27?
Thyrocare Technologies reported consolidated revenue from operations of INR 240.02 crore in Q1 FY27, representing a 24.3% increase year-on-year.
What was Thyrocare Technologies' consolidated net profit in Q1 FY27?
The consolidated Profit After Tax (PAT) for Thyrocare Technologies in Q1 FY27 was INR 51.33 crore, which is a 34.1% increase compared to Q1 FY26.
How did Thyrocare Technologies' standalone profit perform in Q1 FY27?
Thyrocare Technologies' standalone Profit After Tax (PAT) grew by 39.2% year-on-year to INR 50.17 crore in Q1 FY27.
What was the growth in patients and tests conducted for Thyrocare Technologies in Q1 FY27?
In Q1 FY27, Thyrocare Technologies saw a 17% YoY increase in patients to 5.4 Mn and a 28% YoY increase in tests conducted to 55.2 Mn.
How did Thyrocare Technologies' Radiology business perform in Q1 FY27?
Thyrocare Technologies' Radiology business revenue declined 4.0% YoY to INR 13.48 crore in Q1 FY27, reflecting a strategic exit from non-profitable centers, while EBITDA for Radiology grew by 23.1%.
Questions based on this BSE filing only. For information purposes.